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EDITORIAL
Breast screening remains a controversial issue. In many countries it 
is a political issue as much as a medical one, and although there is an 
enormous amount of literature looking at the benefits of the standard 
modalities, there is no consensus about the efficacy of screening.
South Africa (SA) does not have a national mammographic breast 
screening programme. There are both economic and logistical 
reasons for this. The absence of a policy has resulted in alternative 
modalities being promoted as plausible substitutes. If a new modality 
is to be used for screening/symptomatic evaluation of the breasts, it 
should be compared with any of the established and well-researched 
existing modalities. This editorial serves to highlight some of the 
problems with the three commonest modalities being promoted in 
this country at present.
Breast light
Upon review, a limited number of small studies were found evaluating 
the accuracy of a hand-held breast light. The device was used 
on symptomatic patients in a breast clinic in all the studies. The 
Sunderland study found that in 300 women with breast cancer, 
the breast light identified 67% of the cases.[1] In Iran, a study done 
to compare results using the breast light with those from clinical 
breast examination (CBE), mammography or ultrasound showed 
that the breast light missed 40% of the cancers picked up by CBE or 
mammography.[2] A small study from Iraq showed a false-negative 
rate of 19.4% and a false-positive rate of 46.3%. The study concluded 
that these findings preclude the use of the breast light as a screening 
tool for breast cancer.[3] Evaluation of 310 patients between 2012 and 
2013 in Cairo reported much better results with the breast light, with 
sensitivity, specificity, positive predictive value, negative predictive 
value and total accuracy of 93.0%, 73.7%, 91.4%, 77.8% and 88.2%, 
respectively.[4] Shiryazdi et al.[5] concluded in another Iranian study 
that the performance of the breast light in detection of lesions ≤1 cm 
assessed by CBE, mammography and sonography was 4.4%, 7.7% and 
12.5%, respectively, and for masses >4 cm, 65%, 100% and 57.1%.[5] 
The performance of the breast light in detection was significantly 
increased with larger masses (p<0.001), which once again challenges 
the notion that this device can be used as a screening tool equivalent 
to mammography. The most recent publication found was in 2015 in 
the Indian Journal of Cancer, where only 35.8% of lesions that were 
detected by mammography were detected by the breast light.[2]
On its SA website, the breast light is advertised as a self-examination 
adjunct and comes with a disclaimer that ‘Breastlight is not capable 
of detecting all sizes, positions and types of breast abnormalities. It is 
not intended for use as a diagnostic device. PWB Health makes no 
claim that breast cancer, breast lumps or other breast diseases will be 
found when using Breast Light.’[6]
In 2012, the Advertising Standards Authority in the UK upheld a 
complaint made against the claim made by breast light manufacturers 
that ‘it could detect cancer earlier than it would normally be found’. 
There is no evidence that it can, and no published trials have looked 
at its use in screening.[7] Health Canada banned its use in 2010.[8]
Thermography
Clinical thermography has been in use since the 1960s and detects 
temperature variation on the surface of the skin. Breast thermography 
does not provide information on the morphological characteristics of 
the breast, but rather functional information on thermal and vascular 
conditions of the tissue.[9]
A study performed by Sterns et al.[10] indicated large numbers of 
false positives and false negatives with the use of the device. It also 
reported inconsistent interpretation of the thermograph. The most 
recent systematic review available on the modality was published 
in 2012. Fitzgerald et al.[9] reported that the studies reviewed were 
of average quality. Sensitivity for thermography as a screening tool 
was 25% (specificity 74%) compared with mammography. Sensitivity 
for thermography as a diagnostic tool ranged from 25% (specificity 
85%) to 97% (specificity 12%) compared with histology. They 
concluded that there is not sufficient evidence to support the use of 
thermography in breast cancer screening, or sufficient evidence to 
show that thermography provides benefit to patients as an adjunctive 
tool to mammography or to suspicious clinical findings in diagnosing 
breast cancer.[9]
Breast tactile imaging (BTI)/
elastography
This modality measures breast tissue elasticity, which is electronically 
mapped. Data acquired by the device allow calculation of size, shape, 
consistency/hardness and mobility of detected lesions.[11] The aim of 
the tool is cited to be potentially to supplant CBE through its higher 
sensitivity, quantitative record storage, ease of use and inherent 
low cost.[12] There are still limited clinical data on the diagnostic/
screening potential of breast BTI, with most of the studies published 
before 2010 and not much since. In one clinical study that included 
110 patients with a complaint of a breast mass, BTI had a detection 
rate of 94% while physical examination identified 86%.[13] Egorov 
et al.[14] analysed 187 cases, collected at four different clinical sites, 
and reported that BTI produces a reliable image formation of breast 
tissue abnormalities with increased hardness and calculation of lesion 
features.[14] However, these studies are very small and no conclusions 
can be drawn.
Conclusions
There is no current evidence to support the use of the breast light, 
thermography or BTI/elastography as a screening or diagnostic tool 
for breast conditions. Non-governmental organisations should not be 
promoting them, and any practitioner using them should be obliged 
to provide clinical information detailing their shortcomings.
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